Bioxconomy

Published September 24, 2026

Kasvu raises $34m for non-hallucinogenic drug - BioXconomy

Read the full story at Bioxconomy

Kasvu Therapeutics secures funding to advance KTX-0141, a depression treatment that avoids psychedelic hallucinations.